Assisted Reproductive Technology & Gamete Donation

The primary research record in Assisted Reproductive Technology & Gamete Donation is stratified by study design so that meta-analyses and replicated randomised controlled trials (T1–T2) carry greater epistemic weight than observational cohorts (T3–T4) or preclinical laboratory work (T5). Leading graded findings establish the core empirical baseline: [T3] After ED, the PR per fresh embryo transfer was 49.6% (49.2% in 2017) and per FOR 44.9% (43.3% in 2017). [12] [T3] The techniques compared were IVF cycle using patients' own eggs (IVF cycle) versus donor egg cycles.ResultsFor IVF cycles, the voluntary ART register reflected 77.2% of those on the official one, but the corresponding figure was only 34.4% with respect to donated eggs. [24]

Further clinical and mechanistic stratification across the literature demonstrates: [T3] Shared motherhood IVF treatment is becoming increasingly accepted among assisted reproductive techique practitioners and patients in Europe, although data on its overall efficiency remain scarce. [16] [T3] Study questionWhat are the data on ART and IUI cycles, and fertility preservation (FP) interventions reported in 2017 as compared to previous years, as well as the main trends over the years?Summary answerThe 21st ESHRE report on ART and IUI shows the continua [14]

Within the Tree of Knowledge, this field branches into 18 specialised sub-disciplines: Abnormal Cleavage Phenomena and Cytokinetic Anomalies (Identification and clinical implications of aberrant embryonic divisions including direct cleavage (t3-t2 < 5 hours), reverse cleavage, multinucleation, and asymmetric blastomere fragment dynamics); Blastocyst Morphological Grading (Gardner AA/BB) & Zygote Pronuclear Scoring (2PN/1PN) (Synthesise the peer-reviewed record on BB/AA, 1PN/2PN - what grading methods are there for oocytes end embryos: systematic reviews, randomised clinical trials, large cohort studies, quantitative effect sizes, safety signals, and active trials); Blastocyst Grading and Gardner System (Standardized evaluation of blastocoel expansion, inner cell mass (ICM) cohesion, and trophectoderm (TE) cell numbers (AA, AB, BB, CC)); Blastocyst Morphological Grading (Gardner AA/BB System) & Embryo Morphokinetics (Gardner & Schoolcraft blastocyst scoring (expansion stages 1–6, Inner Cell Mass grades A–C, Trophectoderm grades A–C: AA, AB, BA, BB, BC, CC), Day 3 cleavage compaction, time-lapse morphokinetic intervals, euploidy correlation, and live-birth outcomes); Cleavage-Stage Embryo Morphology (Evaluation of cell number, blastomere symmetry, fragmentation percentage, multinucleation, and compaction speed on Day 2 and Day 3).

Chronologically, the field evolved through key inflection points: in 2010, Comparison of IVF cycles reported in a voluntary ART registry with a mandatory registry in Spain. (The techniques compared were IVF cycle using patients' own eggs (IVF cycle) versus donor egg cycles.ResultsFor IVF cycles, the voluntary ART register reflected 77.2% of those on the official one, but the corresponding figure was only 34.4% with respect to donated eggs); in 2021, ART in Europe, 2017: results generated from European registries by ESHRE. (Study questionWhat are the data on ART and IUI cycles, and fertility preservation (FP) interventions reported in 2017 as compared to previous years, as well as the main trends over the years?Summary answerThe 21st ESHRE report on ART and IUI shows the continua); in 2023, ART in Europe, 2019: results generated from European registries by ESHRE†. (After ED, the PR per fresh embryo transfer was 50.5% (49.6% in 2018) and per FOR 44.8% (44.9% in 2018)).

Methodological priorities and open empirical questions queued for the next research sweep across Assisted Reproductive Technology & Gamete Donation focus on resolving subgroup effect sizes, causal mechanisms, and long-term outcomes:

• Large-scale multicentre randomised controlled trials with standardised live-birth and long-term offspring follow-up in Donor eggs in Europe.
• Age- and subgroup-stratified biomarker validation across diverse human populations.